Search research articles
Contact Us
Filters
Showing results (131-140 of 250) with videos related to
Page
of 25
Sort By:
Lancet (London, England)
|
August 13, 2021
Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study
Saad Z Usmani, Alfred L Garfall, Niels W C J van de Donk, et al.
The Lancet. Oncology
|
May 18, 2019
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial
Paul G Richardson, Albert Oriol, Meral Beksac, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 16, 2011
Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma
Bruno Paiva, Joaquin Martinez-Lopez, Maria-Belen Vidriales, et al.
The New England Journal of Medicine
|
December 12, 2022
Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma
Ajai Chari, Monique C Minnema, Jesus G Berdeja, et al.
Annals of Hematology
|
January 20, 2017
Long-term safety and outcome of fludarabine, cyclophosphamide and mitoxantrone (FCM) regimen in previously untreated patients with advanced follicular lymphoma: 12 years follow-up of a phase 2 trial
Laura Magnano, Silvia Montoto, Eva González-Barca, et al.
Haematologica
|
April 26, 2015
Bendamustine, bortezomib and prednisone for the treatment of patients with newly diagnosed multiple myeloma: results of a prospective phase 2 Spanish/PETHEMA trial
María-Victoria Mateos, Albert Oriol, Laura Rosiñol, et al.
The Lancet. Oncology
|
September 7, 2013
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial
Jesus San Miguel, Katja Weisel, Philippe Moreau, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 4, 2023
Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX): A Randomized, Open-Label, Phase III Trial
Meletios A Dimopoulos, Albert Oriol, Hareth Nahi, et al.
The Lancet. Haematology
|
October 9, 2022
Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1/2 trial
Sagar Lonial, Rakesh Popat, Cyrille Hulin, et al.
The Lancet. Haematology
|
July 23, 2019
Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial
Saad Zafar Usmani, Fredrik Schjesvold, Albert Oriol, et al.
Page
of 25
Search research articles
Search
Showing results (131-140 of 250) with videos related to
Sort By:
Page
of 25
Lancet (London, England)
|
August 13, 2021
Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study
Saad Z Usmani, Alfred L Garfall, Niels W C J van de Donk, et al.
The Lancet. Oncology
|
May 18, 2019
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial
Paul G Richardson, Albert Oriol, Meral Beksac, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 16, 2011
Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma
Bruno Paiva, Joaquin Martinez-Lopez, Maria-Belen Vidriales, et al.
The New England Journal of Medicine
|
December 12, 2022
Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma
Ajai Chari, Monique C Minnema, Jesus G Berdeja, et al.
Annals of Hematology
|
January 20, 2017
Long-term safety and outcome of fludarabine, cyclophosphamide and mitoxantrone (FCM) regimen in previously untreated patients with advanced follicular lymphoma: 12 years follow-up of a phase 2 trial
Laura Magnano, Silvia Montoto, Eva González-Barca, et al.
Haematologica
|
April 26, 2015
Bendamustine, bortezomib and prednisone for the treatment of patients with newly diagnosed multiple myeloma: results of a prospective phase 2 Spanish/PETHEMA trial
María-Victoria Mateos, Albert Oriol, Laura Rosiñol, et al.
The Lancet. Oncology
|
September 7, 2013
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial
Jesus San Miguel, Katja Weisel, Philippe Moreau, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 4, 2023
Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX): A Randomized, Open-Label, Phase III Trial
Meletios A Dimopoulos, Albert Oriol, Hareth Nahi, et al.
The Lancet. Haematology
|
October 9, 2022
Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1/2 trial
Sagar Lonial, Rakesh Popat, Cyrille Hulin, et al.
The Lancet. Haematology
|
July 23, 2019
Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial
Saad Zafar Usmani, Fredrik Schjesvold, Albert Oriol, et al.
Page
of 25